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Abstract: Progeroid syndromes show features of accelerated ageing and are used as models for
human ageing, of which Werner syndrome (WS) is one of the most widely studied. WS fibroblasts
show accelerated senescence that may result from p38 MAP kinase activation since it is prevented by
the p38 inhibitor SB203580. Thus, small molecule inhibition of p38-signalling may be a therapeutic
strategy for WS. To develop this approach issues such as the in vivo toxicity and kinase selectivity
of existing p38 inhibitors need to be addressed, so as to strengthen the evidence that p38 itself
plays a critical role in mediating the effect of SB203580, and to find an inhibitor suitable for in vivo
use. In this work we used a panel of different p38 inhibitors selected for: (1) having been used
successfully in vivo in either animal models or human clinical trials; (2) different modes of binding
to p38; and (3) different off-target kinase specificity profiles, in order to critically address the role of
p38 in the premature senescence seen in WS cells. Our findings confirmed the involvement of p38 in
accelerated cell senescence and identified p38 inhibitors suitable for in vivo use in WS, with BIRB 796
the most effective.
Keywords: BIRB 796; cell ageing; fibroblasts; p38 MAP kinase; premature ageing; progeroid
syndromes; SB203580; therapeutics; UR13756; VX-745
1. Introduction
Werner Syndrome (WS) is a rare, autosomal recessive human disorder resulting from mutations in
the WRN gene, which encodes the RECQ3 DNA helicase [1]. Individuals with WS show the premature
onset of many clinical features of old age, including cataracts, skin atrophy, hair-greying and soft
tissue calcification, together with age-related diseases such as type II diabetes, atherosclerosis and
osteoporosis [2,3]. The median life expectancy is 47 years, with the major causes of death being
myocardial infarction or mesenchymal neoplasms. With some exceptions, e.g., the absence of central
nervous system degeneration, WS provides a stunning mimicry of normal ageing and is widely used
as a model disease to investigate the mechanisms underlying normal human ageing [2,3].
Many, but not necessarily all, aspects of WS appear to be related to accelerated cell senescence.
Cultured cells from normal individuals divide only a limited number of times before they enter a state
of viable growth arrest termed cellular senescence, a condition that has been postulated to contribute
to normal human ageing [2]. A key aspect of WS is that WS fibroblasts in vitro have a much reduced
replicative capacity compared to normal fibroblasts [4]. This premature senescence has been postulated
as a major contributor to the accelerated ageing of mitotic tissues in vivo in this syndrome [2]. WS thus
provides an important model system to investigate the link between replicative senescence in vitro and
normal ageing in vivo.
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Skin fibroblasts from individuals with WS grown in vitro show several characteristics of cells
growing under conditions of stress, e.g., they have slow growth rates, an elongated cell cycle, and
an altered morphology characterized by numerous F-actin stress fibres. In many respects, WS cells
resemble fibroblasts that have undergone Stress-Induced Premature Senescence (SIPS) [5]. Of the many
potential stressors that might be operative in WS cells, one that is particularly plausible is a DNA
damage-like signal from the frequent stalled DNA replication forks that are a specific hallmark of cells
deficient in RECQ3 [6]. This process has been termed DNA replication stress, and can activate cell
cycle checkpoints resulting in cell cycle arrest [7].
SIPS is transduced in part by the p38α MAP kinase (MAPK14) signaling pathway [3], and
young WS fibroblasts have elevated levels of activated p38 [5]. Treatment of WS fibroblasts with the
p38α/β inhibitor SB203580 prevents the shortened replicative capacity, increases the growth rate, and
alters the cellular morphology to resemble that seen for normal fibroblasts. This effect is associated
with a down-regulation of p38 activation thus implicating p38 in these processes. Indeed, SB203580
appears to rescue all the in vitro accelerated ageing phenotypes of WS fibroblasts [5]. These data are
consistent with the accelerated replicative senescence seen in WS cells resulting, at least in part, from
activation of the p38 pathway; a SIPS-like state could then contribute to the accelerated ageing seen
in WS individuals. Activation of p38α in WS would also be consistent with the high plasma levels
of inflammatory cytokines such as tumor necrosis factor α (TNFα), and of inflammation-inducing
cell surface molecules such as intercellular adhesion molecule-1 (ICAM-1), that are observed in WS
individuals [8,9]. TNFα and ICAM-1 are known targets of p38α signaling and are associated with
inflammatory conditions such as atherosclerosis [10,11]. This provides a plausible link between the
underlying genetic lesion and the increased level of inflammatory diseases such as atherosclerosis and
type II diabetes that are seen in WS [2]. This in turn raises the possibility of using p38α inhibitors,
or interventions that target other components of this signaling pathway, as the basis for developing
therapeutic approaches in this condition [12].
The bulk of the data on the role of p38 in WS has been based on the use of one inhibitor,
SB203580 [3]. Whilst SB203580 has good selectivity against the α and β p38 isoforms and does
not inhibit the γ and δ isoforms [13], it is not completely specific for p38α/β. For example, it has
been shown to inhibit several other kinases with IC50 values similar to p38α/β, such as casein kinase
1 (CK1) isoforms (in particular CK1δ) and receptor-interacting serine-threonine kinase 2 (RIPK2) [14].
SB203580 also inhibits c-Jun-N-terminal kinase 2 (JNK2) and the kinase c-Raf1, albeit with significantly
higher IC50 values than p38α/β. Of these, CK1 isoforms are involved in the transduction of the
wingless (WNT)-signaling pathway that controls cellular proliferation [15], whereas JNK2 isoforms
can cause growth arrest via stabilization of the cell cycle arrest protein p21WAF1 [16]. The RIPK2
kinase is upstream of p38α and can directly activate it, which makes the observation [5] that p38 is
down-regulated upon SB203580 treatment in WS cells particularly intriguing. Since our previous work
on accelerated senescence in WS fibroblasts was performed using SB203580 at 10 µM, it is formally
possible that at least some of the effects seen with SB203580 are the result of inhibition of targets other
than p38α. In addition, SB203580 does not provide a basis for in vivo studies due its toxicity profile [17].
This present study builds upon our initial observations with SB203580, and in particular seeks
to assess the key issue of inhibitor selectivity by using novel p38 inhibitors with improved and/or
different selectivity profiles, with a view to firmly establishing p38α as the effector in WS premature
cellular senescence, and to find an inhibitor suitable for possible future in vivo use. The rationale behind
the choice of inhibitors, including discussion of their modes of action, protein binding characteristics,
kinase selectivity and toxicity profiles, is described in detail in [3].
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2. Results
2.1. p38 Inhibitors Increase the Growth Rate of WStert Cells
WStert are WS fibroblasts that have been immortalized using human telomerase (see Materials and
Methods) and were grown in standard medium supplemented with SB203580 at a final concentration
ranging from 10 nM to 50 µM (Figure 1a). SB203580 treatment resulted in an increased growth rate
compared to controls even at the lowest concentration used (10 nM). The effect on growth rate increased
steadily with increasing SB203580 concentration, reaching a maximum between 2.5 µM and 10 µM.
However, SB203580 maximally inhibited p38 at 500 nM, and has an IC50 for p38α of approximately
30 nM as measured by us, and others (Figure S1a) [18,19]. At 2.5 µM SB203580 resulted in an increase
in growth rate of approximately 20% compared to DMSO controls.
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A similar situation was seen with BIRB 796, an inhibitor that binds to a novel allosteric binding
site on p38α and has a reported IC50 of 18 nM [20]. We find that BIRB 796 is 100% effective at inhibiting
p38 in the 2 h anisomycin test assay at 10 nM and above (Figure S1b). As with SB203580, BIRB 796
treatment resulted in an increased growth rate compared to controls even at the lowest concentration
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used (10 nM). Indeed, BIRB 796 showed a similar profile of effects to that seen for SB203580 over the
entire concentration range, with the best growth rate increase being 30% at 2.5 µM (Figure 1b). BIRB
796 at 50 nM and above is fully active after 24 h in growth medium (Figure S1c).
UR13756 is an ATP competitive inhibitor that is highly specific for p38α/β with an IC50 of
approximately 80 nM and maximal p38 inhibition above 500 nM in our test assay [21]. UR13756
had little effect on the growth of WStert cells up to 100 nM after which it was increasingly effective,
flattening out between 1 µM and 10 µM, and thereafter becoming inhibitory (Figure 1c). UR13756 was
fully p38 inhibitory after 24 h at 1 µM [21]. The maximal effect on growth rate (10%) was the same as
seen with the lower SB203580 and BIRB 796 levels (Figure 1a,b).
VX-745 has an IC50 for p38α of approximately 30 nM [22]. When WStert cells were grown in
increasing VX-745 concentration no effects were seen below 100 nM (Figure 1d). This concentration is
above that required for 100% p38 inhibition in our 2 h test assay [22]. However, VX-745 was only 100%
effective at inhibiting p38 at 1.0 µM and above after 24 h in growth medium [22]. Interestingly, as with
UR13756, the maximum growth rate increase (10%) was the same as that seen using both SB203580
and BIRB 796 at levels lower than 500 nM.
2.2. The Effects of p53 Abrogation on the Growth Rate of WStert Cells
One route by which p38 activity may result in cellular growth arrest is via activation of p53 or the
stabilization of p21WAF1 [16,23]. To test this, WStert cells were transformed with the E6 oncoprotein
(cells now termed WStert.E6) to abrogate p53 function and then grown in the presence or absence of
SB203580. E6 is a protein produced by human papilloma virus and binds to and degrades p53. As can
be seen, the WStert.E6 cells grew at a faster rate than control WStert cells (p < 0.007), and SB203580
treatment resulted in a further significant growth rate increases in both cases (Figure 2a).
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(b) Immunoblot for the expression of p21WAF1, HSP27 and phosphorylated HSP27 (pHSP27) in WStert
and WStert.E6 cells.
The presence of E6 resulted in a down-regulation of p21WAF1 (Figure 2b; compare lane E6 with
lane D) indicating successful abrogation of p53 function. SB203580 treatment resulted in p21WAF1
down-regulation in both WStert and WStert.E6 cells (Figure 2b; compare lanes SB and E6SB with lanes D
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and E6 respectively). That the SB203580 is active in these cells is shown by its ability to reduce the
levels of phosphorylated HSP27.
These data suggest that p38 and p53 can impinge on proliferation control in WS cells (possibly
via activation of p21WAF1) by different routes as their abrogation or inhibition show synergy of action.
2.3. p38 Inhibition Increases the Replicative Capacity of Primary WS and Normal Fibroblasts
We next assessed the effects of these inhibitors on the replicative capacity of primary WS
fibroblasts and normal dermal fibroblasts (NDFs). The WS fibroblasts used were WS(AG05229)
and WS(AG03141F), and the NDFs used were N(AG04552), N(AG1081) and N(AG13152). The
growth conditions were the same as for the WStert cells. The donors of these NDFs were from
elderly individuals (Table S1). We used VX-745 at 500 nM and UR13756 at 1.0 µM, as these were the
lowest doses that gave a maximal growth response using the WStert cells (see Figure 1). For SB203580
and BIRB 796 we used three doses, 100 nM, 500 nM and 2.5 µM, so as to dissect in more detail the
differential responses seen to these inhibitors. Due to their complexity all data from primary cells are
presented in supplementary Tables S2 to S4, and only summary data are included in Figure 3.
The fibroblast strains were grown to replicative senescence at each inhibitor dose with the
exception of N(AG11081), for which SB203580 and BIRB 796 were only used at 2.5 µM; the results are
presented in Table S2, and plotted in Figure 3a. As can be seen the replicative capacities for fibroblasts
from older individuals and WS are not greatly different. The ability of p38 inhibitors to enhance
cellular growth were calculated as the percentage increase in experimental replicative capacity as
compared to controls for each strain (Table S3). These latter were then averaged and the NDF strains
were compared to the WS strains (Figure 3c). The reason for doing this is that the fibroblast strains had
different experimental replicative capabilities due to different replicative histories, so measuring the
percentage effect is a better measure of the responsiveness of the fibroblasts to p38 inhibition. For all
inhibitor doses the two WS fibroblast strains are on average more responsive to p38 inhibitors than are
NDFs. In addition, in only two situations (indicated in bold in Table S3) was any NDF more responsive
to p38 inhibition than a WS culture. Inhibitors VX-745 and UR13756 were not as effective as the higher
doses of SB203580 and BIRB 796, but were about as effective as the lower doses of SB203580 and BIRB
796. The comparisons that were statistically significantly different between WS fibroblasts and NDFs
were SB203580 at 500 nM (p < 0.01) and 2.5 µM (p < 0.004), and BIRB 796 at 2.5 µM (p < 0.039).
We then extended the study to include several additional strains: three from WS, one from
an elderly normal, one from a middle-aged normal, and three from younger normals (Table S1).
The additional strains from normal individuals were used to explore whether the response to p38
inhibition was limited to fibroblasts from elderly and Werner syndrome donors. All strains were
grown to replicative senescence as before, using SB203580 and BIRB 796 at 2.5 µM, this being the
inhibitor concentrations at which we see the maximal differences between NDFs and WS fibroblasts.
The data are summarized in Tables S2 and S4 and Figure 3b. The first thing of note is that cells from old
individuals were not significantly more responsive to p38 inhibitors than cells from young individuals,
or to cells from a middle-aged donor. However, WS cells were significantly more responsive than
NDFs to both SB203580 and BIRB 796, not only when compared to all the NDFs used (p < 0.00014 and
p < 0.0019 respectively), but also when compared to the cohorts of fibroblasts from the young and old
individuals (Table S4).
These increases were also significant when the actual replicative capacities of the various
fibroblasts strains were analyzed (Figure 3d). The mean replicative capacity of the WS strains was
significantly reduced when compared to the eight NDF strains (18.0˘ 3.6 CPDL compared to 31.1˘ 8.0
CPDL; p < 0.012: Table S2), in agreement with the reported data for WS strains [4,24]. Treatment with
both SB2303580 and BIRB 796 increased the replicative capacity of WS fibroblasts to within the range
seen for inhibitor-treated NDFs (Figure 3d; Table S2), with BIRB 796 more effective than SB203580. This
was seen particularly for the strain WS(AG05229) where BIRB 796 increased the replicative capacity
from 20.9 to 53.7 CPDL, a value that is greater than seen in six of the BIRB 796 treated NDF strains
Pharmaceuticals 2016, 9, 23 6 of 14
(Table S2). Finally, for strain WS(AG12800) the replicative capacity was increased by 490% and 865%
using SB203580 and BIRB 796 respectively, with the latter increasing the replicative capacity from 2
CPDL to 19.3 CPDL (Table S2, and Figure S1d).
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2.4. p38 Inhibitors Prevent the Stressed Cellular Morphology of Primary WS Fibroblasts
One of the principle phenotypic characteristics of primary WS cells is that, even at low population
doubling levels, they display an altered morphology with many of the cells resembling senesced cells,
in that they are enlarged and granular with numerous F-actin stress fibres visible [5]. This is illustrated
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for strain WS(AG05229) in Figure 4a when the cells were treated with fluoresceinisothiocyanate labeled
phalloidin to stain filamentous actin, which clearly visualizes the presence of numerous strongly
stained fibres. Treatment of these cells with p38 inhibitors largely prevented the development of these
actin stress fibres, resulting in cells with a smaller and more regular morphology (Figure 4b–i). It is
clear from Figure 4d that SB203580 at 100 nM was less effective, which was probably due to less than
100% p38 inhibition at this inhibitor concentration (Figure S1a). Similar results were seen for the WS
strain WS(AG03141F) (not shown). For comparison, two NDF strains are shown that lack this stress
fibre phenotype (Figure 4j,k), these being typical of the NDF strains used. Inhibitor treatment had little
effect on the morphology of NDFs (not shown).
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3. Discussion
The rationale behind this study is threefold. First, our use to date of a single p38 inhibitor
(SB203580) is problematic due to its known selectivity issues [19]; thus, it remained unclear whether
p38α was the main kinase involved in premature cell senescence in WS. Second, SB203580 has toxicity
issues [17] that preclude long term in vivo use, motivating the study of other inhibitors that might be
clinically useful. Third, we wished to dissect in more detail any differences in sensitivity of fibroblasts
from different age groups to p38 inhibition.
SB203580 is known to inhibit, at least in vitro, several other kinases that have involvement in the
control of cellular proliferation, namely CK1δ, c-Raf-1, and the various JNKs, in addition to various
other kinases with less well-characterized roles such as RIPK2 [14,19]. The various p38 inhibitors
chosen for this study were synthesized (see [3] for details) and tested for their effects on WS cells.
These inhibitors were of different potencies, were chemically distinct and showed a different (known)
range of off-target selectivities (discussed in [3,25]). To optimize the use of limited primary WS cell
material we first tested these inhibitors on a telomerase-immortalized WS cell tester strain (WStert) that
retains the slow growth and stressed morphology seen in primary WS cells [26].
All of the p38 inhibitors used had a positive effect on the growth rate of WStert cells, although
each was different. The growth rate of WStert cells showed a relatively muted response to the inhibitors
VX-745 and UR13756, although this did occur at doses consistent with p38 inhibition. These are
ATP competitive inhibitors with high specificity for the p38α and p38β kinases, and do not inhibit
the JNKs [27,28] that are in the same family of stress-induced MAP kinases. A larger effect on the
growth rate of the WStert cells was seen for the kinase inhibitors SB203580 and BIRB 769, again at doses
consistent with p38 inhibition. The effect was approximately twice that seen for VX-745 and UR13756.
SB203580 is an ATP competitor with high specificity for the p38α and p38β kinases and is known
not to significantly inhibit the JNKs in cells at the concentrations at which it is most effective [21,29].
Finally, BIRB 796 was most effective at increasing the growth rate of WStert cells and it was the most
potent of all the inhibitors at p38 inhibition. This inhibitor has a different binding mode to the others
and acts both by binding to an allosteric site and as an ATP competitor, and can block p38 activation
as well as its activity [30], attributes that may explain its greater potency. The growth rate increases
found when using these inhibitors, although small, are highly reproducible. In addition to increasing
growth rate, these inhibitors also alleviated the stress-fibre phenotype of the WStert cells (not shown),
a phenotype known to be the result of p38 activation [31,32]. Finally, all inhibitors reduce cellular
growth rates at high concentrations possibly due to non-specific cell toxicity issues at these doses.
With regard to kinases CK1δ, c-Raf1, the JNKs and RIPK2, the data reported in this paper
are supported by observations that inhibition of CK1δ results in complete cessation of growth and
increased apoptosis in WS cells [33], a result not inconsistent with the known biology of CK1δ [34].
Thus, if SB203580 inhibits CK1δ in vivo, cell cycle arrest should occur rather than an extension of
replicative capability. In addition, the p38 inhibitors VX-745 and BIRB 796 do not bind to or inhibit
CK1δ [13,14,28], and both result in an increased replicative capacity in WS cells.
Both SB203580 and BIRB 796 can inhibit c-Raf1 [35,36]. However, it has been noted that
c-Raf1 acts in a negative feedback loop via autophosphorylation, and its inhibition results in c-Raf1
hyper-activation [36]. In addition, in vivo inhibition using various c-Raf1-specific inhibitors led to
up-regulation of compensatory pathways that left its downstream pathways active [33]. These data
suggest that if SB203580 does inhibit c-Raf1 in vivo, such a compensatory effect would be activated,
leading to little effect on growth. That both VX-745 and UR13756 also result in growth enhancement,
albeit to a lesser extent than SB203580, with neither inhibitor affecting c-Raf1 [27,28], provides support
for this, as does the observation that a potent c-Raf1 specific inhibitor had no effect on WS cell
growth [33].
SB203580 has been reported to inhibit the stress-associated JNKs in in vitro assays, albeit with an
IC50 value of between 0.7 µM and 11 µM [18,19]. However, total JNK activity is only partially inhibited
by SB203580 in vivo at concentrations above 10 µM or by BIRB 796 at 2.5 µM and above, and is not
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inhibited by UR13756 and VX-745 [13,21,27,28] (see also Figure S1e showing no inhibition of JNK1/2
by either SB203580 or BIRB 796 at the concentrations used in this work compared to the effect of a
JNK inhibitor [37]). These data, and recent evidence using specific JNK inhibitors which shows that
complete inhibition of JNK has no effect upon replicative capacity in WS cells [37], strongly suggest
that these effects are not due to JNK activity.
The kinase RIPK2 is inhibited by SB203580 at lower doses than needed to inhibit p38α, and its
inhibition suppresses p38α activation [38]. This is interesting as treatment of WS cells with SB203580
suppresses p38 activation [5]. Previous work using RNA interference suggested that RIPK2 was not
involved in WS cell growth [33], although with the caveat that RNA knockdown is not the same as
small molecule inhibition of a kinase. The data presented here using several p38 inhibitors provides
further evidence that RIPK2 is not involved, as the inhibitors VX-745 and BIRB 796 do not bind to or
inhibit RIPK2 [14,28].
Having established that the increased growth rate of WStert cells using SB203580 results from
inhibition of p38α this study then tested the effects of p38 inhibition on primary WS fibroblasts in
comparison to a panel of NDFs. As with the WStert cells, treatment of WS fibroblasts with all the
inhibitors used (VX-745, UR13756, SB202580 and BIRB 796) resulted in increases in replicative capacity.
These increases showed the same pattern in primary cells as seen in the WStert cells, with SB203580
and BIRB 796 being more potent. However, even though the effects were consistently greater for WS
cells than for NDFs, this was only significant for the highest doses of SB203580 and BIRB 796. For the
latter inhibitors, this was true when WS cells were compared to NDFs by either a panel of young
individuals or a panel of old individuals (Figure 3b). The increases were also significant for SB203580
and BIRB 796 when measured as population doublings achieved (CPDL), and resulted in an increase
in the replicative capacity of WS cells from below that seen in NDFs to within the normal NDF range
(Figure 3d). These data support the hypothesis that the shortened replicative capacity seen in primary
WS fibroblasts is due in large part to p38-dependent SIPS.
The effects of the inhibitors SB203580 and BIRB 796 were essentially the same for the fibroblasts
from old and young individuals, suggesting that p38-dependent SIPS is not occurring to a higher level
in cells from older individuals, which fits with the evidence that fibroblasts from older individuals
do not have a significantly reduced replicative capacity compared to fibroblasts from younger
individuals [39]. These data also strongly suggest that WS fibroblasts are not simply a ‘phenocopy’
of cells from an old individual, and provide support for the concept of SIPS leading to a reduced
capability of WS cells to undergo proliferation as a result of p38α activation, probably due to ongoing
DNA replication stress [7]. This replication stress manifests as a difficulty in replicating certain DNA
sequences, such as the common fragile sites (CFSs) and telomeres, and WS fibroblasts show elevated
telomeric truncations and expression of CFSs [40,41].
This concept raises the question as to how inhibiting the p38-dependent SIPS leads to an increase
in the replicative capacity of WS fibroblasts, since DNA replication stress should still be occurring.
It is possible that by preventing SIPS, a second mechanism is activated to process the replication stress
to a successful resolution and thus allow cell division, and in this regard it is interesting to note that
p38 activation is down-regulated in SB203580 treated cells [5], suggesting that the stress is alleviated.
Recent evidence has demonstrated that in the absence of the RECQ3 helicase, a second pathway is
indeed activated in WS cells, one that involves activation of the MUS81 endonuclease and the RECQL5
and RECQ2 helicases [42–44], and increased RECQL5 expression can overcome replication stress in
human cells [45]. It is possible that in WS activation of p38 leading to SIPS is a rapid process to protect
cells from excessive DNA damage, with the secondary back-up pathways being slow acting. When p38
is inhibited this then allows the back-up pathways to operate leading to resolution of the replication
stress and progression though the cell cycle. This is, of course, speculative, but evidence is increasing
to support this viewpoint, although these back-up pathways are not fully understood [7,43].
Our data suggest that the most potent inhibitor is BIRB 796. As all of these inhibitors target p38α,
some with potencies in in vitro assays almost as high as BIRB 796, why is the latter more effective?
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It is possible that BIRB 796 is simply more stable in the growth media during these in vitro studies, a
possibility supported by the reduced potency of inhibitors such as VX-745 seen in the 24 h assays and
over longer time periods [22]. A second possibility is that this is due to BIRB 796 having a different
binding mode from the other inhibitors, since it binds not only to the ATP-binding pocket but also
to an adjacent allosteric site; thus it binds more tightly to p38α and is not readily displaced by ATP
competition [20]. A third possibility relates to the altered binding mode as BIRB 796 can inhibit
all four p38 isoforms (unlike the other inhibitors that only target p38α and p38β) [13], and recent
data suggest that premature cellular senescence can result from activation of p38γ and p38δ [46,47].
As p38γ causes cell cycle arrest by phosphorylation of p53 thus up-regulating p21WAF1, whereas
p38α stabilizes p21WAF1 directly and appears not to phosphorylate p53 [16,46,47], the observation
that abrogation of p53 by E6 and p38α inhibition by SB203580 show a synergistic effect on cellular
growth rates and p21WAF1 levels suggest the possibility that both p38α and p38γ may be involved
in the premature senescence seen in WS cell that then may explain the increased potency of BIRB
796. As BIRB 796 has been used extensively in clinical trials [3], this inhibitor may be useful for future
in vivo studies, such as in the existing WS mouse model [48] to test the idea that SIPS in WS does indeed
lead to the accelerated ageing in this syndrome. In addition, as accelerated ageing in WS is associated
with increased inflammatory conditions and senescent cells produce inflammatory cytokines, the
observation that BIRB 796 suppresses this cytokine production [49] suggests that, if SIPS is operating
in WS, then p38 inhibitors may have clinical utility to alleviate these inflammatory conditions.
Finally, even though the inhibitors VX-745 and UR13756 are less effective than BIRB 796, they
do reduce the accelerated senescence seen in WS cells and alleviate the stressed cellular morphology.
Also, as VX-745 is tolerated in mouse for up to six months [3] this inhibitor may be useful for
proof-of-principle in vivo studies in the mouse WS model [48]. In addition, as this work confirms
a role for p38 isoforms in premature cellular senescence, it can underpin future in vivo studies for
p38 inhibitors that are still at the developmental stage that may have improved clinical applicability
in humans.
4. Materials and Methods
4.1. Protein Kinase Inhibitors
The protein kinase inhibitor SB203580 was obtained from Tocris Chemical Co. (Bristol, UK).
The kinase inhibitor BIRB 796 was synthesized according to [30]. VX-745 was synthesized according
to [22]. UR13756 was synthesized according to [21]. The synthesis routes, modes of action and protein
binding characteristics for these inhibitors are described in detail in [3].
4.2. Cells and Cell Growth
Adult dermal primary fibroblasts were obtained from the Coriell Cell Repositories (Camden,
NJ, USA) and are listed in Table S1. All cell strains have been given a prefix to indicate their group
followed by the Coriell strain identifier in parentheses; for example, N(AG04552) is the AG04552 strain
of normal dermal fibroblasts (NDFs). Primary NDFs were chosen from a range of elderly and younger
individuals with a range of replicative capabilities. WStert are WS(AG03141) fibroblasts that have been
immortalized by the ectopic expression of human telomerase and have been described previously [26].
The human telomerase immortalized HCA2tert cells have been described previously [22].
Due to limited supplies of primary WS fibroblasts, initial growth experiments to determine the
effects of novel kinase inhibitors on cellular growth were performed using WStert cells. Despite being
immortal, these telomerized cells retain the slow growth rate typical of primary WS cells and show
a similar response to SB203580 treatment [26]. Thus, these cells can be used to test the effects of
modulators of the p38-signalling pathway prior to their use on primary cells.
Cells were grown in DMEM as previously described [50]. Population doublings (PDs) achieved
at each cell passage were calculated according to the formula: PDs = log(Nt/No)/log2, where Nt
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is number of cells counted and No is number of cells seeded. The number of PDs at each passage
was then totaled to give a cumulated population doubling level (CPDL). For experiments using
immortalized cells the proliferation rate was calculated by dividing the CPDL by the number of days
of the experiment concerned and expressed as PDs/day. For primary cells the CPDL is quoted in the
Supplementary Tables. For assessing the effects of the various kinase inhibitors the culture medium
was supplemented with the inhibitor dissolved in DMSO, with the medium being replaced daily
unless otherwise stated. For controls an equivalent volume of the inhibitor solvent (DMSO) was added
to the medium.
4.3. Determination of the Ability of Inhibitors to Inhibit the p38 Pathway
The ability of individual compounds to inhibit the p38 stress-signaling pathway was tested in
anisomycin-treated HCA2tert cells using an ELISA-based readout (Cell Signalling, NEB, Hitchin, UK)
as described in [51]. Kinase activity was detected using antibodies specific for the phosphorylated
forms of HSP27 and antibodies that detect total levels of HSP27, the degree of activation being recorded
as the ratio of phospho-protein/total protein; the data for SB203580 and BIRB 796 are given in Figure
S1a,b. Data for the other inhibitors has been published previously [21,22].
To test the efficacy of these inhibitors under experimental growth conditions, the pre-incubation
time with selected inhibitor concentrations was increased to 24 h to match the daily feeding regimen of
the growth experiments; the assay was otherwise identical (see Figure S1c).
4.4. Immunofluorescence Microscopy
Actin staining for immunofluorescence microscopy was performed essentially as described [5].
4.5. Immunoblot Analysis
All procedures for the immunoblot analyses were carried out as described [5]. Antibodies
used were: mouse monoclonal anti-HSP27 (G31), rabbit polyclonal anti-phospho(S82)-HSP27,
rabbit polyclonal anti phospho(T183/Y185)-JNK1/2, rabbit monoclonal anti-JNK1/2 (56G8), rabbit
monoclonal anti-c-Jun (60A8) (Cell Signalling, New England Biolabs, Hitchin, UK) and mouse
monoclonal anti-p21WAF1 (6B6; Becton Dickinson, Swindon, UK).
4.6. Retroviral Gene Transfer
Amphotropic retrovirus vectors expressing the HPV16 E6 oncoprotein were constructed and gene
transfer was carried out as described previously [52].
5. Conclusions
Four p38 inhibitors (SB203580, BIRB 796, VX-745 and UR13756) have been used to test the role
of p38α MAPK in the premature senescence seen in primary fibroblasts from the premature ageing
Werner syndrome. All four successfully reduced the accelerated cell senescence to some degree,
although BIRB 796 was by far the most potent, and its use extended the replicative capacity of WS
cells to within the range seen for fibroblasts from normal individuals. As these inhibitors all have
different protein binding modes and specificity profiles (their only common target being p38), these
data essentially confirm that premature WS cell senescence is due to activation of p38. Also, as some
of these inhibitors are tolerated in the mouse for up to six months, they may be useful for future
proof-of-principle in vivo studies to try to establish a link between in vitro premature cell senescence
and in vivo premature ageing in the mouse model of Werner syndrome. This in turn may underpin
future in vivo human studies into whether p38 inhibitors may have clinical potential in human ageing.
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/9/2/23/s1,
Figure S1: Supplementary figures, Figure S2: Figure 4, Table S1: fibroblast strains used in this study, Table S2:
Comparison of CPDL for inhibitor treated normal and WS fibroblasts, Table S3: Percentage increases in replicative
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capacity for primary fibroblasts using p38 inhibitors, Table S4: Percentage increases in replicative capacity using
SB203580 and BIRB796.
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